Payment overview · 2025
General Payments
$206.54
11 reported records · 8 companies
Healthcare provider profile · identity verified
Jody Carmony
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SHELBYVILLE, IN · NPI 1962806067
Verified facts
What the public records show
CMS Open Payments records show Jody Carmony received $206.54 in general payments during 2025 across 11 reported records.
Axsome Therapeutics, Inc. accounted for 37.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.74 | 37.6% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $28.60 | 13.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.99 | 9.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.49 | 8.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.82 | 8.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.64 | 8.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.18 | 6.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.08 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.54 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $77.74 | 4 | 2025 |
Source payment records
|
|||||
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $28.60 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 64 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
133 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 424 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 68 |
| Lisinopril | Lisinopril | 174 | 42 |
| Omeprazole | Omeprazole | 169 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 44 |
| Gabapentin | Gabapentin | 151 | 39 |
| Buspirone Hcl | Buspirone Hcl | 149 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 141 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 42 |
| Ozempic | Semaglutide | 133 | 18 |
| Losartan Potassium | Losartan Potassium | 129 | 36 |
| Metformin Hcl | Metformin Hcl | 123 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 37 |
| Ezetimibe | Ezetimibe | 104 | 25 |
| Alendronate Sodium | Alendronate Sodium | 100 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 22 |
| Sertraline Hcl | Sertraline Hcl | 97 | 25 |
| Allopurinol | Allopurinol | 70 | 17 |
| Montelukast Sodium | Montelukast Sodium | 69 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 23 |
| Farxiga | Dapagliflozin Propanediol | 64 | 19 |
| Potassium Chloride | Potassium Chloride | 60 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 12 |
| Trazodone Hcl | Trazodone Hcl | 55 | 16 |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 17 |
| Alprazolam | Alprazolam | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 12 |
| Celecoxib | Celecoxib | 41 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 14 |
| Jardiance | Empagliflozin | 39 | 14 |
| Pregabalin | Pregabalin | 39 | 11 |
| Memantine Hcl | Memantine Hcl | 38 | 11 |
| Furosemide | Furosemide | 37 | 12 |
| Famotidine | Famotidine | 36 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Carvedilol | Carvedilol | 31 | 12 |
| Atenolol | Atenolol | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Prednisone | Prednisone | 29 | 24 |
| Simvastatin | Simvastatin | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 13 |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 13 |
| Sucralfate | Sucralfate | 24 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 20 |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 15 |
| Torsemide | Torsemide | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| V-Go 20 | Sub-Q Insulin Device, 20 Unit | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.54 · 11 records | Axsome Therapeutics, Inc. | Auvelity, FARXIGA, FREESTYLE LIBRE 3, LEQVIO, OMNIPOD, VRAYLAR, Veozah | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error